Analysts say the partial U.S.-China trade deal doesn't touch on thorny issues plaguing both sides, and warn talks could break down again.World Economyread more
Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
A technical recession occurs when there are two consecutive quarters of economic contraction.Asia Economyread more
"Deepfakes" are being used to depict people in fake videos they did not actually appear in, and can potentially affect elections, diplomacy and how markets move, experts say.Technologyread more
Chinese President Xi Jinping warned on Sunday that any attempt to divide China will be crushed.China Politicsread more
Syria's Kurds said Syrian government forces agreed Sunday to help them fend off Turkey's invasion.World Newsread more
U.S. President Donald Trump said that both sides reached a "very substantial phase one deal" that will address intellectual property and financial services concerns and...Asia Marketsread more
Hagibis dropped record amounts of rain for a period in some spots, according to meteorological officials, causing more than 20 rivers to overflow.Asia Newsread more
A spokesperson for the U.S.-backed Syrian Democratic Forces (SDF) has issued a stark warning to the international community.World Newsread more
This could kick off a takeover battle for Shire, a perennial takeover target. It initially built a niche with amphetamine-based drugs to treat ADHD, but has used the revenues from these treatments to expand into lucrative orphan diseases and specialty pharmaceuticals. U.S. based AbbVie, which was spun out of larger Abbot Laboratories last year, now has until July 18 to make a full and final offer.
Shire has previously stressed the importance to it of remaining independent. Flemming Ornskov, its chief executive who started at the company last year, has pursued an aggressive acquisitions policy, and the company expects to more than double its 2013 annual product sales to US$10 billion by 2020.
AbbVie is advised by JPMorgan, while Shire is advised by Citi, Evercore and Morgan Stanley.
- By CNBC's Catherine Boyle